Inspire Medical Systems (NYSE:INSP) Trading Down 5.4% on Analyst Downgrade

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) traded down 5.4% during mid-day trading on Tuesday after Zacks Research downgraded the stock from a strong-buy rating to a hold rating. The stock traded as low as $71.62 and last traded at $71.6260. 577,956 shares changed hands during mid-day trading, a decline of 47% from the average daily volume of 1,081,862 shares. The stock had previously closed at $75.72.

Other research analysts also recently issued reports about the company. Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday, June 30th. JPMorgan Chase & Co. lifted their price target on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Weiss Ratings upgraded shares of Inspire Medical Systems from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. Finally, Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Hold” and a consensus target price of $66.50.

Insider Activity at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.20% of the stock is owned by company insiders.

Institutional Trading of Inspire Medical Systems

Several large investors have recently bought and sold shares of the business. Apollon Wealth Management LLC raised its position in shares of Inspire Medical Systems by 5.6% in the first quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock valued at $206,000 after buying an additional 212 shares during the last quarter. Havemeyer Place LP acquired a new stake in shares of Inspire Medical Systems during the 4th quarter worth $39,000. Hantz Financial Services Inc. raised its position in shares of Inspire Medical Systems by 194.0% in the 4th quarter. Hantz Financial Services Inc. now owns 685 shares of the company’s stock worth $63,000 after buying an additional 452 shares during the period. Pictet Asset Management Holding SA increased its stake in Inspire Medical Systems by 12.1% during the first quarter. Pictet Asset Management Holding SA now owns 5,018 shares of the company’s stock worth $259,000 after acquiring an additional 542 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Inspire Medical Systems by 85.0% during the second quarter. GAMMA Investing LLC now owns 1,221 shares of the company’s stock worth $54,000 after buying an additional 561 shares during the period. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Price Performance

The firm’s 50-day moving average price is $60.79 and its 200-day moving average price is $53.18. The company has a market cap of $2.00 billion, a price-to-earnings ratio of 14.95, a price-to-earnings-growth ratio of 5.39 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.38. The firm had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The firm’s quarterly revenue was down 7.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, sell-side analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year.

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for treating moderate to severe obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed for patients who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses a small implantable pulse generator, a breathing-sensing lead and a stimulation lead.